Granules India Q1FY26 consolidated net profit rises 60% YoY
Granules India Limited's unaudited consolidated financial results for Q1FY26 show a net profit of ₹1,799.63 million, a 60% increase from ₹1,126.36 million in Q1FY25. Revenue from operations climbed to ₹14,767.74 million. Standalone net profit was ₹717.46 million. The Board also approved the issuance of warrants.
*this image is generated using AI for illustrative purposes only.
Granules India Limited reported a consolidated net profit of ₹1,799.63 million for the quarter ended June 30, 2026, a significant increase from ₹1,126.36 million in the corresponding period of the previous year. The pharmaceutical manufacturer's revenue from operations rose to ₹14,767.74 million, compared to ₹12,101.06 million in Q1FY25, driven by growth in product sales. The unaudited financial results were approved by the Board of Directors on July 21, 2026.
Q1 Financial Performance
The company's standalone net profit for the quarter stood at ₹717.46 million, while total standalone revenue from operations was ₹8,018.77 million. The following table summarizes the key consolidated financial metrics:
| Metric | Q1FY26 (₹ in millions) | Q1FY25 (₹ in millions) |
|---|---|---|
| Total revenue from operations | 14,767.74 | 12,101.06 |
| Total expenses | 12,386.37 | 10,560.15 |
| Profit for the period | 1,799.63 | 1,126.36 |
| Basic EPS (₹) | 7.26 | 4.64 |
Key Highlights
- Consolidated net profit for Q1FY26 stood at ₹1,799.63 million, up from ₹1,126.36 million in the prior year.
- Revenue from operations increased to ₹14,767.74 million from ₹12,101.06 million.
- Standalone profit for the period was ₹717.46 million compared to ₹694.85 million in the same quarter last year.
- The Board approved the issuance of 25,000,000 warrants on a preferential basis in December 2025, with shareholders approving the move in January 2026.
The statutory auditors, S.R. Batliboi & Associates LLP, conducted a limited review of the unaudited standalone and consolidated financial results. The company operates in one reportable business segment of pharmaceutical products, including ingredients and intermediaries.
What factors are expected to sustain the revenue growth momentum for the remainder of FY26?
How will the proceeds from the preferential warrant issuance be allocated to drive future expansion?
Are there any anticipated regulatory hurdles or market headwinds that could impact profitability in the coming quarters?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
